Arcoxia? FDA Says ‘Fuggedabotit!’
Make a commentBy Ed Silverman // April 27th, 2007 // 9:46 am
“We are disappointed with today’s decision,” says a glum Peter Kim, Merck’s chief scientist. “We pursued FDA approval of Arcoxia because we believe strongly that new medicines are needed for patients whose osteoarthritis pain is inadequately managed with currently available therapies.”
Disappointed, yes. But is anyone surprised?
The Merck statement.[tags]Arcoxia, Merck[/tags]